TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06052787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Description: Cerebrolysin, a mixture of free amino acids and low molecular weight peptides, has a neurotrophic factor-like activity with immediate pleiotropic neuroprotective activity and long-term multimodal effects on endogenous post-lesional regulation. Cerebrolysin has been suggested to exert beneficial effects on neurobehavioural functions, cognitive performance , and neuro-motor recovery , as part of initial therapy in severe and moderate acute TBI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Description: Cerebrolysin, a mixture of free amino acids and low molecular weight peptides, has a neurotrophic factor-like activity with immediate pleiotropic neuroprotective activity and long-term multimodal effects on endogenous post-lesional regulation. Cerebrolysin has been suggested to exert beneficial effects on neurobehavioural functions, cognitive performance , and neuro-motor recovery , as part of initial therapy in severe and moderate acute TBI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amantadine sulfate
Description: The dopaminergic agonist amantadine enhances presynaptic dopamine release and inhibits dopamine reuptake, resulting in an increased amount of dopamine in the synaptic cleft. Amantadine may also increase the density of postsynaptic dopamine receptors and alter the conformation of these receptors. Amantadine acts as an NMDA receptor antagonist, blocking glutamate, an NMDA channel activator. This effect may be responsible for amantadine's possible beneficial effect soon after TBI
Study: NCT06089694

Intervention type: DEVICE
Intervention: Enabling Sensor Research Holter Mode feature
Description: The Sensor Research Holter Mode feature within the Crome and Cobalt ICD and CRT-D devices will be enabled for a short period of time at the In-clinic Testing Visit to allow for desired data collection.
Study: NCT06295744

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: WBI with SIB delivered over 5 fractions
Study: NCT06279130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: balstilimab
Description: Anti programmed cell death protein-1 (anti-PD1)
Study: NCT05685095

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical training
Description: Supervised gait training program 3 times a week, 12 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical training
Description: Supervised gait training program 3 times a week, 12 weeks
Study: NCT05474690

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel + Carboplatin + Trastuzumab + Pertuzumab
Description: Subjects who met the inclusion conditions were randomly divided into TCbHP group and ECHP-THP group according to 1:1.~Stratified at randomization by the following factors: T, N, HER2 expression (HER2 protein 3+ vs HER2 protein 2+ but FISH+), and hormone receptor status (HR positive vs HR negative).~TCbHP regimen drug dose: docetaxel 75 mg/m2 + carboplatin (AUC=6) + trastuzumab (first loading dose 8 mg/kg, sequential maintenance dose 6 mg/kg) + pertuzumab Antibiotics (the initial loading dose of 840 mg, and the sequential maintenance dose of 420 mg), every 21 days as a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (Epirubicin + Cyclophosphamide - Docetaxel) + (Trastuzumab + Pertuzumab)
Description: Dosage of ECHP-THP regimen: epirubicin 90mg/m2+cyclophosphamide 600mg/m2 followed by docetaxel 90mg/m2, trastuzumab (first loading dose 8 mg/kg, sequential maintenance dose 6 mg /kg) + Pertuzumab (the initial loading dose of 840 mg, and the sequential maintenance dose of 420 mg), every 21 days as a cycle.
Study: NCT05078424

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Description: CBT is a well-established, evidence-based intervention frequently used for easing depressive and anxiety symptoms. The intervention will be delivered for 6-7 sessions, each session lasts for 1.5 hours, in the format of a group for a period of 6-7 weeks by frontline social or youth workers trained by professional CBT clinicians. Core treatment components include mood monitoring, emotion education, behavioural activation, emotion cycle/ ABC model, identification of automatic thoughts, and cognitive restructuring. It is designed to improve youths' abilities/ skills in handling their moods to have better emotional management.
Study: NCT04774042

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Infloran probiotic
Description: Infloran

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HAC probiotic
Description: HAc probiotic

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Infloran placebo
Description: Infloran placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Infloran placebo
Description: Infloran placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HAC placebo
Description: HAC placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: HAC placebo
Description: HAC placebo
Study: NCT05532098

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dry Needling
Description: Dry Needling will be done for the patients with ADD of TMJ in the retrodiscal tissue and superior joint space .

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRP
Description: Patients with ADD are administered with 1ml of PRP into the retrodiscal tissue and the superior joint space. PRP will be prepared by method proposed by Okuda et al., 2003. Reinjection will be given after 2 weeks if required.
Study: NCT05051865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: camrelizumab
Description: camrelizumab combined with SHR1020 for advanced melanoma

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR1020
Description: camrelizumab combined with SHR1020 for advanced melanoma
Study: NCT06575296

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT06342063

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blood Flow Restriction Therapy
Description: Patients wear a personalized tourniquet pressure system on their involved thigh while they perform a series of leg press machine exercises. This tourniquet is inflated.
Study: NCT06575296

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revumenib
Description: Given PO
Study: NCT05924802

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone Ester
Description: Added to water or lemonade 3 times per day.
Study: NCT05955586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPR720
Description: SPR720 1000 mg (250 mg\*4 capsules) will be administered orally.
Study: NCT05176431

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ESWT (wave type: focused)
Description: Extracorporeal Shock Wave Therapy, device: Electronica, Pagani, Italy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ESWT (wave type: radial)
Description: Extracorporeal shock wave therapy, device: Electronica, Pagani, Italy

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: ESWT (wave type: sham)
Description: Extracorporeal shock wave therapy, device: Electronica, Pagani, Italy
Study: NCT06473493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alverine
Description: 180 mg/day (1 capsule orally, 3 times a day), taken continuously for 24 weeks
Study: NCT05346913

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered Cognitive Behavioural Therapy(ICBT)
Description: ICBT provides online structured self-help modules over several months based on the principles of CBT in combination with weekly guidance through emails and telephone calls. The course comprises 6 online lessons that provide psychoeducation about: 1) symptom identification and the cognitive behavioural model; 2) thought monitoring and challenging; 3) de-arousal strategies and pleasant activity scheduling; 4) graduated exposure/pacing; 5) memory and attention; and 6) relapse prevention. Participants will also have the opportunity to ask any questions regarding the content of the program materials and will receive a response from their Guide within 48-72 hours. Guide will spend \~15 mins. per week/per participant. All Guides have completed a university program (psychology or social work) and are registered clinicians or students working under supervision of a registered clinician.
Study: NCT06342063

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Blood Flow Restriction Therapy Sham
Description: Patients wear a personalized tourniquet pressure system on their involved thigh while they perform a series of leg press machine exercises. This tourniquet is not inflated.
Study: NCT05924802

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Added to water or lemonade 3 times per day.
Study: NCT05067101

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Capsule Sparing Cystectomy (CSC)
Description: Adopt endoscopic enucleation technology to preserve the prostate capsule and part of the urinary control support structure to help restore urinary control and erectile functions
Study: NCT05516641

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soluble Corn Fiber
Description: once daily additive to diet
Study: NCT05743049

Intervention type: OTHER
Intervention: Obtaining blood for analysis of various circulating biomarkers
Description: 4 tbsp of blood in a 1-week period, occurring no more frequently than 4 times in an 8-week period
Study: NCT06468696

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suturing the cervical linea alba during endoscopic thyroid surgery.
Description: Suturing the cervical linea alba during endoscopic thyroid surgery.

Intervention type: GENETIC
Group type: OTHER
Intervention: Performing transcriptome sequencing
Description: Performing transcriptome sequencing

Intervention type: GENETIC
Group type: OTHER
Intervention: Performing transcriptome sequencing
Description: Performing transcriptome sequencing

Intervention type: GENETIC
Group type: OTHER
Intervention: Performing transcriptome sequencing
Description: Performing transcriptome sequencing

Intervention type: GENETIC
Group type: OTHER
Intervention: Performing transcriptome sequencing
Description: Performing transcriptome sequencing
Study: NCT05996848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cagrilintide
Description: Participants will receive 2.4 mg cagrilintide subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Participants will receive 2.4 mg semaglutide subcutaneously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: Participants will receive 2.4 mg semaglutide subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Semaglutide
Description: Participants will receive placebo matched to semaglutide subcutaneously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Semaglutide
Description: Participants will receive placebo matched to semaglutide subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cagrilintide
Description: Participants will receive placebo matched to cagrilintide subcutaneously.
Study: NCT06077734

Intervention type: OTHER
Intervention: In vitro analyse
Description: In vitro analysis on isolated mesoangioblasts obtained from muscle biopsies

Intervention type: OTHER
Intervention: In vitro analyse
Description: In vitro analysis on isolated mesoangioblasts obtained from muscle biopsies

Intervention type: OTHER
Intervention: In vitro analyse
Description: In vitro analysis on isolated mesoangioblasts obtained from muscle biopsies
Study: NCT05516641

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: once daily additive to diet
Study: NCT04758429

Intervention type: DEVICE
Intervention: Machine-learning Algorithm
Description: System technology/Software

Intervention type: DEVICE
Intervention: Machine-learning Algorithm
Description: System technology/Software
Study: NCT04889573

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: The blood samples will be collected from healthy volunteers : 7 tubes of 7 ml with anti-coagulant Héparine Lithium and 1 tube of 7ml with anti-coagulant EDTA
Study: NCT05764018

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Negligible amount of maltodextrin in flavoured drink solution containing 6 mg/kg body mass caffeine provided 45 minutes before exercise

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Negligible amount of maltodextrin in flavoured drink solution containing 6 mg/kg body mass caffeine provided 45 minutes before exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoxia
Description: Participants will be breathing from a hypoxic gas mixture (13% O2) for the duration of the exercise bout. This will simulate an altitude of approximately 3500 m.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hypoxia
Description: Participants will be breathing from a hypoxic gas mixture (13% O2) for the duration of the exercise bout. This will simulate an altitude of approximately 3500 m.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Negligible amount of maltodextrin in flavoured drink solution provided 45 minutes before exercise.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Negligible amount of maltodextrin in flavoured drink solution provided 45 minutes before exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normoxia
Description: Participants will be breathing from ambient air (\~21% O2) for the duration of the exercise bout. This will provide no hypoxic stimulus as the laboratory is located relatively near sea level (295 m)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normoxia
Description: Participants will be breathing from ambient air (\~21% O2) for the duration of the exercise bout. This will provide no hypoxic stimulus as the laboratory is located relatively near sea level (295 m)
Study: NCT04275778

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plaquenil 200Mg Tablet
Description: Hydroxychloroquine will be taken at a dosage of 400 mg / day until delivery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: placebo will be taken at a dosage of 400 mg / day until delivery
Study: NCT05368025

Intervention type: DEVICE
Intervention: Mobili-T/Noona
Description: Use of two mobile health systems over a period of 6 months
Study: NCT05773326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: TORISEL® (temsirolimus) is a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma.
Study: NCT05067101

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional Radical Cystoprostatectomy (CRC)
Description: According to the consensus standard program, remove the accessory tissues including the bladder, prostate and seminal vesicles
Study: NCT05624684

Intervention type: DIAGNOSTIC_TEST
Intervention: Multiplex respiratory PCR
Description: The BIOFIRE® FILMARRAY® Pneumonia plus Panel
Study: NCT04740268

Intervention type: DEVICE
Group type: OTHER
Intervention: Straberi
Description: The patient's entire face will be treated with the Straberi microneedling devise.~The following settings will be used as a treatment protocol. Needle length between .02- 1.55 mm

Intervention type: DEVICE
Group type: OTHER
Intervention: Straberi
Description: The patient's entire face will be treated with the Straberi microneedling devise.~The following settings will be used as a treatment protocol. Needle length between .02- 1.55 mm
Study: NCT05707598

Intervention type: PROCEDURE
Intervention: Laparoscopic surgery
Description: The laparoscopic approach was used for the treatment of clinical T4b colorectal cancer
Study: NCT05646082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab in Combination Antiretroviral Therapy
Description: Patients will receive dostarlimab at the fixed dose of 500 mg dose Q3W for the first 4 doses followed by a fixed 1000 mg dose Q6W until week 48 of treatment.
Study: NCT06174181

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Preservative-free ophtalmic lubricant emulsion
Description: Use of a preservative-free ophtalmic lubricant emulsion continous during 6 months

Intervention type: OTHER
Group type: OTHER
Intervention: Routine treatment
Description: Use of a preservative-free ophtalmic lubricant emulsion after each intravitreal injection during few days
Study: NCT06452628

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan mobilizations
Description: The duration of the intervention will be 4 weeks, 3 sessions a week, a total of 12 sessions will be given to the study participants. Each session will last for 30 minutes. Conventional physical therapy will be given to participants along with Mulligan mobilizations.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Release Technique
Description: The duration of the intervention will be 4 weeks, 3 sessions a week, a total of 12 sessions will be given to the study participants. Each session will last for 30 minutes. Conventional physical therapy will be given to participants along with the Active release technique.

Intervention type: OTHER
Group type: OTHER
Intervention: Mulligan mobilizations with active release technique
Description: The duration of intervention will be 4 weeks, 3 sessions a week, a total of 12 sessions will be given to the study participants. Each session will last for 30 minutes. Conventional physical therapy will be given to participants along with mulligan mobilizations with active release technique.
Study: NCT05971004

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arthrys (Collagen Peptide solution)
Description: one injection of collagen peptide solution (Tiss'You, Republic of San Marino) at the site of the inflamed ligament attachment point

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depo medrol
Description: one injection of depo-medrol at the site of inflamed ligament attachment point (femoral condyle), combined with oral slow-acting symptomatic drugs (glucosamine 1500mg, atrodar 50mg) for 3 consecutive months.
Study: NCT06442852

Intervention type: OTHER
Intervention: exposure
Description: The observed exposure factor was the expression level of synaptic associated mirna in the serum of patients with Alzheimer's disease and healthy volunteers

Intervention type: OTHER
Intervention: exposure
Description: The observed exposure factor was the expression level of synaptic associated mirna in the serum of patients with Alzheimer's disease and healthy volunteers
Study: NCT04626843

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent fast
Description: 16/8 fasting method: fast for 16 hours of the day with an 8 hours feeding window for a duration of 3 months.
Study: NCT06226506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test (T) Aprepitant injection
Description: Specification: Aprepitant injection 4.4ml∶32mg. Produced and supplied by Qilu Pharmaceutical (Hainan) Co.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test (T) Aprepitant injection
Description: Specification: Aprepitant injection 4.4ml∶32mg. Produced and supplied by Qilu Pharmaceutical (Hainan) Co.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference (R) Aprepitant injection
Description: Specification: Aprepitant injection 4.4ml∶32mg. Produced by Heron Therapeutics, Inc and supplied by Qilu Pharmaceutical (Hainan) Co.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference (R) Aprepitant injection
Description: Specification: Aprepitant injection 4.4ml∶32mg. Produced by Heron Therapeutics, Inc and supplied by Qilu Pharmaceutical (Hainan) Co.
Study: NCT04777643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Participants will receive a single 600mg oral dose of Epidiolex (cannabidiol) 2 hours prior to fMRI scanning.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a single oral dose of placebo 2 hours prior to fMRI scanning.
Study: NCT06164444

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention: Reusable drapes and gowns
Description: Reusable drapes and gowns used during surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Disposable (single-use) drapes and gowns
Description: Disposable drapes and gowns used during surgery.
Study: NCT05943327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AG06474
Description: Oral Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AG06474
Description: Oral Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AG06474
Description: Capsule
Study: NCT05817968

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intelligent Esophageal Pressure Catheter (iEPC)
Description: Placement of the iEPC nasogastric catheter with solid state sensor for esophageal manometry.~Comparator: Esophageal balloon catheter (NutriVent).
Study: NCT04975971

Intervention type: DRUG
Intervention: Dextenza 0.4Mg Ophthalmic Insert
Description: DEXTENZA is a corticosteroid intracanalicular insert placed in the punctum, a natural opening in the eye lid, and into the canaliculus and is designed to deliver dexamethasone to the ocular surface for up to 30 days without preservatives.
Study: NCT05742087

Intervention type: OTHER
Intervention: Clinical examination
Description: The examination performed by the clinician of the patient will be analyzed from the cohort as previously explained.

Intervention type: OTHER
Intervention: electroneuromyography (ENMG)
Description: Data from the ENMGs will be extracted from the cohort and analyzed.
Study: NCT05790655

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: oPRP
Description: Prepared sample from patient's own blood collected and processed

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oPRP
Description: Prepared sample from patient's own blood collected and processed
Study: NCT05391776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TST002 Injection
Description: This single dose study, ascending with phase I dose-escalation principles from 200mg up to 1200mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: This single dose study, ascending with phase I dose-escalation principles from 200mg up to 1200mg.